×××ר××
×צפ××× ×××××¢ ××ר×× ×ר×פ××× ×ש
××××× ×¡ ××ש××× ×. ×× ××× × ×¨×©×× ××× ×¡ ×
×רש×× ×ר×פ××× ××× ×©× ×קצ××¢×ת רפ×××××.
× ×ª×× × ×ª×¨×פ×
××רש×
| ק×××¦× ×¤×¨×ק×××××ת (ATC4)
|
L01XL
Antineoplastic cell and gene therapy
|
| ×ר××× ×¤×¢×× (ATC5)
|
Â
|
| צ×רת ×ת×
|
ת××-×ר××× - I.V
|
| צ×רת ××× ××
|
DISPERSION FOR INFUSION
××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר××
|
| ×ת××××
|
Yescarta is indicated for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.YESCARTA is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy. Limitation of Use :YESCARTA is not indicated for the treatment of patients with primary or secondary central nervous system lymphoma.Yescarta is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy
|
| × ×ª×× × ×ס×
|
ת×ר×× ××××× ×ס×
- 30/01/2020
|
×××××ת ×ס×
- תר××¤× ×××××ת ×ר×ש×× ×¢'× ×¨××¤× ××××× ×× ××××× ××רת
|
×ת×××× ×ס×
| ×ת×××× |
ת×ר×× ××××× |
ת××× ×§××× × |
Class Effect |
××¦× ×××× |
×ס×ס ×××××ת
|
| ××××ר×× ×××××× ××××פ××× ×××רת ×× ×¢×××× (רפרק××ר×ת) ×ס×× Diffuse large B cell lymphoma, ×××ר ×©× × ×§××× ××פ×× ×××¢××.
|
30/01/2020 |
××× ×§×××××× |
|
Diffuse large b cell lymphoma |
|
| ××××ר×× ×××××× ××××פ××× ×××רת ×× ×¢×××× (רפרק××ר×ת) ×ס×× Primary mediastinal B-cell lymphoma, ×××ר ×©× × ×§××× ××פ×× ×××¢××
|
30/01/2020 |
××× ×§×××××× |
|
Primary mediastinal B-cell lymphoma |
|
| ××××ר×× ×××××× ××××פ××× ×¤×××ק××ר×ת ×××רת ×× ×¨×¤×¨×§××ר×ת ×××ר ש×××©× ×§××× ××פ×× ×§××××× ×××¢××. ××××× ××××ª× ×××× ××××× ×××× ×××פ×× ×××ת ×××× â Axicabtagene ciloleucel, Tisagenlecleucel.
|
01/02/2023 |
××× ×§×××××× |
|
Follicular lymphoma |
|
| ××××ר×× ×××××× ××××פ××× ×ס×× HGBL (High grade B cell lymphoma) ש×××¨× ×ת×× 12 ×××ש×× ×ת×× ××××××××× ×תרפ×× ×©× ××ª× × ××§× ××פ×× ×¨×ש××, ×× ×¢×××× ×××××××××× ×תרפ×× ×©× ××ª× × ××§× ××פ×× ×¨×ש××. ××××× ××××ª× ×××× ××××× ×××× ×××פ×× ×××× ×××× â Axicabtagene ciloleucel, Tisagenlecleucel
|
01/02/2023 |
××× ×§×××××× |
|
HGBL, High grade B cell lymphoma |
|
| ××××ר×× ×××××× ××××פ××× ×ס×× DLBCL (Diffuse large B cell lymphoma) ש×××¨× ×ת×× 12 ×××ש×× ×ת×× ××××××××× ×תרפ×× ×©× ××ª× × ××§× ××פ×× ×¨×ש××, ×× ×¢×××× ×××××××××× ×תרפ×× ×©× ××ª× × ××§× ××פ×× ×¨×ש××. ××××× ××××ª× ×××× ××××× ×××× ×××פ×× ×××× ×××× â Axicabtagene ciloleucel, Tisagenlecleucel.
|
01/02/2023 |
××× ×§×××××× |
|
DLBCL, Diffuse large B cell lymphoma |
|
|
ש×××ש ×ס×
-
|
×ס×רת ××××× ×ס×
- ×. ×תר××¤× ×ª×× ×ª× ×××פ×× ××קר×× ××××:
- 1. ××××ר×× ×××××× ××××פ××× ×ס×× DLBCL (Diffuse large B cell lymphoma) ש×××¨× ×ת×× 12 ×××ש×× ×ת×× ××××××××× ×תרפ×× ×©× ××ª× × ××§× ××פ×× ×¨×ש××, ×× ×¢×××× ×××××××××× ×תרפ×× ×©× ××ª× × ××§× ××פ×× ×¨×ש××. ××××× ××××ª× ×××× ××××× ×××× ×××פ×× ×××× ×××× â
- Axicabtagene ciloleucel, Tisagenlecleucel. 2. ××××ר×× ×××××× ××××פ××× ×××רת ×× ×¢×××× (רפרק××ר×ת) ×ס×× Diffuse large B cell lymphoma, ×××ר ×©× × ×§××× ××פ×× ×××¢××. ××××× ××××ª× ×××× ××××× ×××× ×××פ×× ×××ת ×××× â Axicabtagene
- ciloleucel, Tisagenlecleucel. 3. ××××ר×× ×××××× ××××פ××× ×××רת ×× ×¢×××× (רפרק××ר×ת) ×ס×× Primary mediastinal B-cell lymphoma, ×××ר ×©× × ×§××× ××פ×× ×××¢××.
- 4. ××××ר×× ×××××× ××××פ××× ×ס×× HGBL (High grade B cell lymphoma) ש×××¨× ×ת×× 12 ×××ש×× ×ת×× ××××××××× ×תרפ×× ×©× ××ª× × ××§× ××פ×× ×¨×ש××, ×× ×¢×××× ×××××××××× ×תרפ×× ×©× ××ª× × ××§× ××פ×× ×¨×ש××. ××××× ××××ª× ×××× ××××× ×××× ×××פ×× ×××× ×××× â Axicabtagene ciloleucel, Tisagenlecleucel5. ××××ר×× ×××××× ××××פ××× ×¤×××ק××ר×ת ×××רת ×× ×¨×¤×¨×§××ר×ת ×××ר ש×××©× ×§××× ××פ×× ×§××××× ×××¢××. ××××× ××××ª× ×××× ××××× ×××× ×××פ×× ×××ת ×××× â Axicabtagene ciloleucel, Tisagenlecleucel.
- ×. ××ª× ×תר××¤× ×××××¨× ×××¢×©× ××¤× ××¨×©× ×©× ××××× ××××××××××.
|
|
| ×ת××ת ××× ××
|
Posology and method of administration
|
| ×ת××××ת × ××
|
Contraindications
|
| ת×פע×ת ×××××
|
Undesirable effects
|
| ת××××ת ××× ×ª×¨×פת××ת
|
Interaction with other medicinal products and other forms of interaction
|
| ש×××ש ×××ר××× ××× ×§×
|
Pregnancy and Lactation
|
| פר×ק×××× ××ק×
|
Pharmacodynamic Properties
|
| פר×ק×ק×× ××ק×
|
Pharmacokinetic Properties
|
| ×¢××× ×ר××¤× ××××ר×ת ××¢×××
|
Â
Â
|
| ××פ×ש ×××ר××
|
×××ר×× ×-PubMed
|
| ××××¢ ×רשת
|
RxList WebMD Drugs.com
|
| ×©× ×צר×
|
KITE PHARMA, INC., USA
|
| ×©× ××¢× ×ר×ש××
|
GILEAD SCIENCES ISRAEL LTD
|
| ר×ש×××
|
ת×ר×× ××ש×: 6/2018. ר×ש××× ×ת×ר××:
|
| ת×ר×× ×¢×××× ××ר××
|
29/01/2024
|
ת××× ×ª ×ר×××
ת×ר×× ×¢××××: 29/01/2024
KITE
×סקר×× - Yescarta
true
השינוי האחרון נעשה בֹ־3 בדצמבר 2025 ב־18:45
